ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 198 filers reported holding ROYALTY PHARMA PLC in Q4 2020. The put-call ratio across all filers is 2.07 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,560,550 | -92.2% | 57,500 | -91.2% | 1.05% | -90.9% |
| Q2 2023 | $20,002,211 | -45.7% | 650,690 | -36.3% | 11.50% | -45.0% |
| Q1 2023 | $36,829,650 | +3.9% | 1,022,194 | 0.0% | 20.91% | -0.1% |
| Q4 2022 | $35,462,047 | -13.7% | 1,022,194 | 0.0% | 20.94% | -12.7% |
| Q3 2022 | $41,072,000 | -7.1% | 1,022,194 | -2.8% | 24.00% | -3.2% |
| Q2 2022 | $44,222,000 | -58.4% | 1,051,895 | -61.4% | 24.80% | -40.2% |
| Q1 2022 | $106,277,000 | -42.0% | 2,727,854 | -40.7% | 41.47% | -15.9% |
| Q4 2021 | $183,355,000 | -35.5% | 4,601,152 | -41.5% | 49.30% | -19.0% |
| Q3 2021 | $284,152,000 | -25.5% | 7,862,542 | -15.5% | 60.85% | -8.3% |
| Q2 2021 | $381,307,000 | +0.4% | 9,302,445 | +6.9% | 66.33% | -13.0% |
| Q1 2021 | $379,735,000 | -64.7% | 8,705,551 | -59.5% | 76.23% | -12.9% |
| Q4 2020 | $1,074,938,000 | – | 21,477,282 | – | 87.53% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $294,957,000 | 88.74% |
| Vantage Consulting Group Inc | 8,705,551 | $379,735,000 | 76.23% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $116,930,000 | 72.07% |
| HARVARD MANAGEMENT CO INC | 10,714,284 | $467,357,000 | 26.11% |
| ROBERT WOOD JOHNSON FOUNDATION | 970,151 | $4,231,798,000 | 21.59% |
| Brown University | 381,759 | $16,652,000 | 11.44% |
| Overbrook Management Corp | 771,155 | $33,638,000 | 7.48% |
| SpiderRock Advisors, LLC | 778,800 | $34,236,000 | 4.79% |
| Renaissance Capital LLC | 452,948 | $19,758,000 | 2.93% |
| Lagoda Investment Management, L.P. | 104,835 | $4,573,000 | 2.28% |